Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 941678-49-5
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the clinical use of ruxolitinib during breastfeeding. Because ruxolitinib is 97% bound to plasma proteins, the amount in milk is likely to be low. The manufacturer recommends that breastfeeding be discontinued during ruxolitinib therapy and for 2 weeks after the last dose for the oral tablets and for 4 weeks after the last dose for the topical cream.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Ruxolitinib
CAS Registry Number
941678-49-5
Drug Class
Breast Feeding
Milk, Human
Antineoplastic Agents
Enzyme Inhibitors
Protein Kinase Inhibitors
Signal Transduction Inhibitors
Janus Kinase Inhibitors
JAK Inhibitors
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- Review Deuruxolitinib.[Drugs and Lactation Database (...]Review Deuruxolitinib.. Drugs and Lactation Database (LactMed®). 2006
- Review Baricitinib.[Drugs and Lactation Database (...]Review Baricitinib.. Drugs and Lactation Database (LactMed®). 2006
- Review Ibrutinib.[Drugs and Lactation Database (...]Review Ibrutinib.. Drugs and Lactation Database (LactMed®). 2006
- Review Vemurafenib.[Drugs and Lactation Database (...]Review Vemurafenib.. Drugs and Lactation Database (LactMed®). 2006
- Review Abrocitinib.[Drugs and Lactation Database (...]Review Abrocitinib.. Drugs and Lactation Database (LactMed®). 2006
- Ruxolitinib - Drugs and Lactation Database (LactMed®)Ruxolitinib - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...